Company Overview
Immix Biopharma, Inc. operates as a clinical-stage biopharmaceutical entity focused on the development of chimeric antigen receptor cell therapy specifically targeting light chain Amyloidosis and immune-mediated diseases within the United States and Australia markets. The company functions within the broader Healthcare sector, specifically the specialized Biotechnology industry, which implies a focus on early-stage research and development rather than established commercial revenue generation. Its current market capitalization stands at $471.83M, while the annual revenue is not available in the provided data, and the organization employs 18 individuals. These valuation figures indicate that the company holds a significant market cap relative to its extremely small workforce and lack of reported revenue, suggesting that the market value is derived almost entirely from the potential of its pipeline assets, such as NXC-201 for relapsed/refractory AL Amyloidosis, rather than current cash flow or sales performance.
Financial Health
The reported revenue for the trailing twelve months is not available, the net income is $-23,562,836, and the EBITDA stands at $-23,836,024. The substantial gap between the unavailable revenue figure and the significant negative net income reveals a cost structure dominated by high research and development expenses that far outpace any current sales generation. The company's free cash flow is $-6,578,808, which indicates that the organization is consuming cash reserves to fund its operations and clinical trials rather than generating liquidity from business activities. All three margin metrics are reported at 0.0%; the gross margin is 0.0%, the operating margin is 0.0%, and the profit margin is 0.0%, each indicating that the company has not yet achieved profitability or is operating at a stage where revenue does not cover the direct costs of goods sold or operational overhead. The company holds $15.95M in cash against $1.11M in debt, resulting in a debt-to-equity ratio of 13.39, which suggests a highly leveraged balance sheet relative to equity but maintains a conservative absolute debt load given the cash on hand. The current ratio is 1.53, which indicates that the company possesses sufficient current assets to cover its short-term liabilities with a margin of safety of 53% above the 1.0 benchmark. The return on equity is -182.5% and the return on assets is -66.5%, metrics that reveal management is currently unable to generate positive returns on the capital invested in the company due to ongoing losses.
Valuation Assessment
The trailing P/E ratio is N/A due to the lack of net income, while the forward P/E is -11.05, implying that analysts or market participants are pricing in future earnings recovery or that the stock is valued based on non-traditional multiples given the negative earnings profile. The price-to-book ratio is 35.64, which indicates a substantial market premium over the company's book value, suggesting investors are valuing the intangible assets and pipeline potential significantly higher than the recorded net assets. The price-to-sales ratio is N/A and the EV/EBITDA is -11.93, metrics that suggest the stock is being valued on alternative criteria such as clinical trial milestones or asset potential rather than traditional revenue multiples or earnings coverage. The 52-week high is $11.61 and the 52-week low is $1.34; without a specific current price provided in the facts, the valuation context relies on the wide trading range where the stock has experienced extreme volatility, moving from a low of $1.34 to a high of $11.61. The beta is 0.26, which means the stock exhibits low price volatility relative to the broader market, moving significantly less than the S&P 500 in response to general market fluctuations.
Growth & Income
The revenue growth year-over-year is N/A and the earnings growth year-over-year is N/A, preventing a direct comparison of earnings growth rates versus revenue growth, but the absence of historical growth data is consistent with a clinical-stage company that has not yet commercialized its products. As a non-dividend payer, the company does not distribute a dividend yield or maintain a payout ratio, which explains that the entity reinvests all available earnings, or lack thereof, back into research and development to advance its chimeric antigen receptor cell therapy programs. Since the company does not pay dividends and has negative earnings, the income profile is entirely dependent on capital appreciation derived from the success of its lead product NXC-201 and the progression of its clinical trials in light chain Amyloidosis. The overall growth and income profile is characterized by a high-risk, high-reward structure typical of early-stage biotechnology firms where income generation is secondary to pipeline advancement and clinical validation.